Trending Stock News

Mylan N.V. (MYL) Analysts See $1.40 EPS; 4 Analysts Covering INSYS Therapeutics, Inc. (INSY)

Analysts expect Mylan N.V. (NASDAQ:MYL) to report $1.40 EPS on March, 7.They anticipate $0.17 EPS change or 10.83% from last quarter’s $1.57 EPS. MYL’s profit would be $751.00 million giving it 7.53 P/E if the $1.40 EPS is correct. After having $1.10 EPS previously, Mylan N.V.’s analysts see 27.27% EPS growth. The stock increased 1.18% or $0.49 during the last trading session, reaching $42.14. About 3.42 million shares traded. Mylan N.V. (NASDAQ:MYL) has declined 7.73% since February 20, 2017 and is downtrending. It has underperformed by 24.43% the S&P500.

Among 6 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Insys Therapeutics had 22 analyst reports since August 4, 2015 according to SRatingsIntel. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Tuesday, April 12 with “Buy” rating. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) rating on Sunday, August 13. Jefferies has “Buy” rating and $1400 target. Zacks downgraded INSYS Therapeutics, Inc. (NASDAQ:INSY) on Friday, August 14 to “Buy” rating. The company was initiated on Thursday, April 14 by Janney Capital. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) rating on Thursday, August 4. Jefferies has “Buy” rating and $22 target. RBC Capital Markets maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Thursday, September 22 with “Outperform” rating. The company was maintained on Wednesday, March 9 by JMP Securities. The company was maintained on Thursday, August 3 by RBC Capital Markets. The firm has “Buy” rating by Jefferies given on Friday, September 15. The firm has “Buy” rating by RBC Capital Markets given on Thursday, June 1. See INSYS Therapeutics, Inc. (NASDAQ:INSY) latest ratings:

03/11/2017 Broker: Jefferies Rating: Buy Old Target: $14 New Target: $11 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $8.0 Maintain
18/10/2017 Broker: Jefferies Rating: Buy New Target: $14.0 Maintain
09/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $14.0 Maintain
15/09/2017 Broker: Jefferies Rating: Buy New Target: $14.0 Maintain

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $22.61 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 26.06 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Investors sentiment decreased to 0.33 in 2017 Q3. Its down 1.00, from 1.33 in 2017Q2. It worsened, as 3 investors sold Mylan N.V. shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 155,019 shares or 7.99% less from 168,486 shares in 2017Q2 were reported. 139,930 are owned by Gulf State Bank (Uk). Vantage Inv Advsrs Limited Co reported 712 shares.

Among 22 analysts covering Mylan Inc. (NASDAQ:MYL), 14 have Buy rating, 0 Sell and 8 Hold. Therefore 64% are positive. Mylan Inc. had 66 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 23 by Mizuho. The firm earned “Hold” rating on Thursday, December 21 by Cantor Fitzgerald. UBS maintained Mylan N.V. (NASDAQ:MYL) rating on Monday, October 10. UBS has “Buy” rating and $60 target. The firm has “Buy” rating given on Thursday, January 11 by Goldman Sachs. Zacks downgraded the stock to “Buy” rating in Monday, August 17 report. As per Wednesday, October 4, the company rating was maintained by Cowen & Co. As per Tuesday, September 6, the company rating was maintained by RBC Capital Markets. The firm has “Hold” rating given on Thursday, August 27 by Zacks. Deutsche Bank maintained Mylan N.V. (NASDAQ:MYL) rating on Friday, August 7. Deutsche Bank has “Buy” rating and $66 target. The rating was maintained by Cantor Fitzgerald on Wednesday, August 9 with “Hold”.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $571.14 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

The stock decreased 3.83% or $0.31 during the last trading session, reaching $7.79. About 636,945 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 5.69% since February 20, 2017 and is downtrending. It has underperformed by 22.39% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *